Aug 6, 2026 earnings call — Brepocitinib launch and busy readout calendar
Brepocitinib expected to launch imminently with multiple top-line readouts scheduled in second half of 2026.
Revenue $0.0B (est $0.0B) · EPS $-0.33 (est $-0.30)
Key quotes
"The upcoming potential brepocitinib launch in DM, which should happen imminently assuming everything goes as we hope and expect it will with FDA."
"We're hoping to see a clear signal on PVR."
Analyst Q&A 11
brepo DM launch metrics
Q (Brian Chen · JPMorgan): Analyst asked what early metrics will be available to track the DM launch and asked about PH-ILD baseline (nintedanib use) and implications for fibrosis vs emphysema and for 6-minute walk and PVR endpoints.
A: Management said they will provide limited early launch metrics and focus on talking to patients and physicians. They designed PHocus to limit emphysema so the drug can help the right patients. They expect a clear PVR signal but do not expect much clarity on 6-minute walk because the study is not powered for it.
"We expect if the drug is all active, we will." — Matthew Gline (CEO)
6-minute walk and formulary timing
Q (David Risinger · Leerink Partners): Analyst asked what 6-minute walk improvement would be clinically meaningful in a large trial, and asked about cadence of formulary reviews for rare disease launches and other pipeline opportunities to start new studies.
A: Management said they will focus on having an approvable therapy rather than a specific numeric 6-minute walk bar, noting patients are very sick and 6-minute walk can be noisy. They said Priovant is engaging payers and will use medical exceptions and support to ensure access. They also said every program in the known and possibly unknown pipeline could lead to new trials or indications over the next year.
"I think every single one of the programs that the world is aware of in our pipeline as well as potentially ones that the world is not yet aware of in our pipeline." — Matthew Gline (CEO)
PVR translation to PH-ILD
Q (Samantha Semenkow · Citi): Analyst asked how PVR reductions seen in PAH patients translate to PH-ILD patients and whether disease differences could affect PVR magnitude.
A: Management said the study is designed to test that translation and they must wait for results; Phase I and PAH data looked good on PVR. They noted PH-ILD lungs differ from PAH lungs so pharmacodynamics could differ, but inhaled vasodilation delivers drug to healthy lung tissue and that matters.
"The first unfortunate answer to that question is we're just going to have to see what we see." — Matthew Gline (CEO)
off-label JAK use and Phase III risks
Q (Prakhar Agrawal · Cantor Fitzgerald): Analyst asked what percent of dermatomyositis patients use off-label JAKs and whether those patients would rapidly switch to brepo; also asked biggest risk for Phase III NIU given geographic variation.
A: Management said off-label JAK use varies by physician but is low single-digit to mid-single-digit percent. They said switches will depend on individual doctors' practices and they'll facilitate where appropriate. For Phase III, they worry most about variability in placebo responses in immunology trials and noted geographic variation exists but is a typical feature of such studies.
"I think what we've said publicly is a low single-digit percentage or mid-single-digit percentage of dermatomyositis patients have experience with these things." — Matthew Gline (CEO)
launch analogs for brepo in DM
Q (Andy Chen · Wolfe): Analyst asked which historical launch analogs they are using to model brepo's patient or market share curve in dermatomyositis.
A: Management said there is no direct analog because no targeted therapy launch has happened in dermatomyositis before. They will focus on the dermatomyositis docs and patients and accept that being a pioneer means following their own path rather than another drug's trajectory.
"The truth is there has never been a launch of a targeted therapy in dermatomyositis before." — Matthew Gline (CEO)
difficult-to-treat RA next steps
Q (Yatin Suneja · Guggenheim): Analyst asked whether one or more additional studies are needed for difficult-to-treat RA and what to expect from the randomized withdrawal data.
A: Management said they will give a full update later this year and that the randomized withdrawal data may or may not be usable as a pivotal study depending on results. They are planning an FDA discussion this fall which will inform the exact design and regulatory strategy.
"I think at some level, the results of that study may inform whether it is usable or not as one of our pivotal studies, et cetera." — Matthew Gline (CEO)
mosli monotherapy vs combo data timing
Q (Yaron Werber · TD Cowen): Analyst asked if monotherapy and combo mosli data will be released together and asked about CS phase II translation to CSAMI>50% endpoint.
A: Management said monotherapy and combo data will not be released at the same time because the combo study started later and is still enrolling. They said the monotherapy readout will arrive sooner and is expected to provide most of the needed information. For CS, they reported meaningfully higher rates of greater than 50% CSAMI response in the treatment arm versus placebo in Phase II.
"We will not release the monotherapy data and the combo data at the same time because the combo study started much later and is enrolling now." — Matthew Gline (CEO)
D2T RA disclosure and Graves competition
Q (Thomas Smith · Leerink Partners): Analyst asked whether Part 2 randomized withdrawal data will be shared before the FDA meeting and how they view the competitive landscape in Graves disease and future studies for 1402.
A: Management said their hope is to provide a fulsome update later this year including Part 2 data and the FDA conversation, shared together if possible. On Graves, they said the market has large unmet need, multiple mechanisms can coexist, and being first gives them an opportunity to shape treatment; competition is about building the market rather than beating a single rival.
"Our hope and expectation would be to give a fulsome update later this year on everything all at once for D2T RA." — Matthew Gline (CEO)
NIU readout timing and sNDA plans
Q (Yasmeen Rahimi · Piper Sandler): Analyst asked whether they will narrow guidance ahead of the second-half 2026 readout, what the bar for success is, and the expected timing to file an sNDA after data.
A: Management said they doubt they will provide more specific timing guidance than already given and will read the study when data are clean. They said the bar is a successful study that would support registration, and if positive they expect the team to move quickly to file an sNDA as they did previously.
"I doubt that we're going to provide more specific timing guidance at this point than we have." — Matthew Gline (CEO)
CLE proof-of-concept and DM clinic targeting
Q (Samuel Slutsky · LifeSci Capital): Analyst asked what will be reported in the initial CLE proof-of-concept readout and how many clinics they will target for the initial dermatomyositis launch and patient concentration.
A: Management said the CLE study is a small 12-week proof-of-concept comparing 600 versus placebo and that the 12-week 600 versus placebo result will be reported first along with other data. They said they will not disclose exact DM targeting now but noted about 200 myositis referral centers treat roughly half of U.S. patients and those centers are important.
"The thing that we'll be reporting first is that 12 weeks for 600 versus placebo." — Matthew Gline (CEO)
managing placebo in Graves; 1402 in MG/CIDP
Q (Alexander Thompson · Stifel): Analyst asked how they will manage placebo response in Graves studies given ATD titration and disease variability, and how 1402 might fit into MG and CIDP treatment landscapes.
A: Management said setting high enough endpoints should make spontaneous remission and placebo manageable, and they will not disclose detailed titration specifics. For MG, they expect 1402 should work based on prior FcRn data and see a large market with room for multiple classes; for CIDP they see more opportunity to influence the treatment paradigm and be a major player if data are strong.
"if you set the bar high enough on the endpoints, these are just not patients who are spontaneously remitting." — Matthew Gline (CEO)